Details for Patent: 10,117,836
✉ Email this page to a colleague
Which drugs does patent 10,117,836 protect, and when does it expire?
Patent 10,117,836 protects QULIPTA and UBRELVY and is included in two NDAs.
This patent has forty-two patent family members in thirteen countries.
Summary for Patent: 10,117,836
| Title: | Tablet formulation for CGRP active compounds |
| Abstract: | The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released. |
| Inventor(s): | Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu |
| Assignee: | Merck Sharp and Dohme LLC |
| Application Number: | US15/115,026 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,117,836 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Device; Dosage form; |
Drugs Protected by US Patent 10,117,836
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-001 | Sep 28, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-002 | Sep 28, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-003 | Sep 28, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,117,836
| PCT Information | |||
| PCT Filed | January 30, 2015 | PCT Application Number: | PCT/US2015/013672 |
| PCT Publication Date: | August 13, 2015 | PCT Publication Number: | WO2015/119848 |
International Family Members for US Patent 10,117,836
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015214502 | ⤷ Start Trial | |||
| Australia | 2019226239 | ⤷ Start Trial | |||
| Australia | 2021245229 | ⤷ Start Trial | |||
| Australia | 2021409718 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
